The utilization of IFN-α in the treatment of human B cell lymphoma dates back to the late 1970s, beginning with the use of natural IFN-α in murine models of leukemia and lymphoma (Additional file 1: Table S1) [29–31]. This evidence concerns the gene IFNA2 and lymphoma.